

Lourens T Bloem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2401525/publications.pdf>

Version: 2024-02-01

9
papers

95
citations

1683354
5
h-index

1473754
9
g-index

9
all docs

9
docs citations

9
times ranked

94
citing authors

#	ARTICLE	IF	CITATIONS
1	Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 684-691.	2.3	34
2	Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 426-435.	2.3	12
3	Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing. <i>Modern Pathology</i> , 2022, 35, 1110-1120.	2.9	12
4	Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. <i>Clinical and Translational Science</i> , 2021, 14, 1566-1577.	1.5	10
5	The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.5	8
6	Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 773-783.	1.4	6
7	Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer. <i>Oncology and Therapy</i> , 2016, 4, 103-116.	1.0	5
8	Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2169-2179.	1.1	5
9	Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle – a focus on benefits and risks. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-10.	1.0	3